Biotechnology
Multiple patients substantially exceed expected survival at low dose levels; absence of dose-limiting toxicities supports escalation to doses up to 100x higher Trial expansion reflects growing confidence in intra-peritoneal CAR-T delivery and introduceslymphodepletion to potentially enhance efficacy Anixa to participate in Water Tower Research fireside chat at 11:00am ET on February 10, 2026to discuss trial…
Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader platform Excerpt from the Press Release: SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) — Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the first patient has been dosed in the Phase 1/2 clinical trial (NCT07300241)…
Excerpt from the Press Release: WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) — Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that it has completed enrollment in the Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary…
KTX-2001 being evaluated both as a monotherapy and in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC) Shinta Cheng, M.D., Ph.D., joins company as Chief Medical Officer Excerpt from the Press Release: CAMBRIDGE, Mass., Feb. 5, 2026 /PRNewswire/ — K36 Therapeutics, Inc. (“K36”), a privately held clinical-stage biotechnology company developing novel targeted therapies for…
Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant Excerpt from the Press Release: REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) — Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results…
Patent Enhances IP Estate for Lead Asset; Combined with Anticipated Biologics Exclusivity, Market Protections Extend Over 20 Years Excerpt from the Press Release: PRINCETON, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills…
Excerpt from the Press Release: ALAMEDA, Calif.–(BUSINESS WIRE)–Scribe Therapeutics, Inc. (Scribe), a biotechnology company pioneering highly engineered CRISPR technologies designed to reshape the treatment of disease by enabling earlier intervention, improved outcomes, and longer, healthier lives, announced plans to enter the clinic in mid-2026 with STX-1150, its lead product candidate for the treatment of hypercholesterolemia,…
– Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS-mutated mCRC – – Data support selection of 30 mg onvansertib dose for registrational program in first-line RAS-mutated mCRC – – Data validate previously reported positive results from…
Company provides 2026 corporate outlook highlighting multiple clinical catalysts across first-in-class cardioendocrine pipeline MAR002 Phase 1 Data: Robust, durable IGF-1 suppression supports potential for biweekly to monthly dosing; Phase 2/3 study initiation expected mid-2026 MAR001 Phase 2b TYDAL-TIMI 78 Study Enrollment Nearing Completion: multiple data readouts expected throughout 2026; advancing half-life-extended MAR001-HLE designed for infrequent,…
67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or well controlled disease at 12 weeks With a median duration of follow up…